| Catalog No. | HY583066 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | VH-VH' |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | sIL6R, Interleukin-6 receptor subunit alpha, CD126, IL-6R 1, IL-6R subunit alpha, Membrane glycoprotein 80, gp80, IL6R, IL-6RA, IL-6 receptor subunit alpha, IL-6R-alpha, ALB, Albumin |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P08887 & P02768 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -154°C. |
|---|
| Alternate Names | Bispecific,(20A11-9mer-ALB11),ALX-0061,CAS:1628814-88-9 |
|---|
| Background | Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
